Codexis Inc (NAS:CDXS)
$ 5 0.07 (1.42%) Market Cap: 406.89 Mil Enterprise Value: 358.48 Mil PE Ratio: 0 PB Ratio: 5.56 GF Score: 53/100

Codexis Inc at UBS Global Life Science Conference (Virtual) Transcript

May 23, 2022 / 08:15PM GMT
Release Date Price: $10.51 (+0.19%)
John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate

Hi. I'm John Sourbeer, UBS' life science tools and pharma services analyst. Welcome to the last panel of the day, of day 1 of the UBS Healthcare Conference. We have -- we're hosting Codexis for this fireside chat, and we have John Nicols, President and CEO.

John J. Nicols
Codexis, Inc. - President, CEO & Director

Pleasure to be here. Thanks.

Questions & Answers

John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate

Just to get things started, can you provide an overview of Codexis' business model and the different spaces you're involved in as a company? How did you get here? And where do you want to go in the future?

John J. Nicols
Codexis, Inc. - President, CEO & Director

Awesome. Yes, pleasure. So Codexis, we're a 20-year-old company. We've been focused our entire history on enzymes as a class of products to discover and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot